文献速递妇科

AVB-500联合紫杉醇或聚乙二醇脂质体阿霉素治疗铂耐药复发性卵巢癌的1b期研究

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-08-30

这项1b期研究评估了AVB-500联合紫杉醇或聚乙二醇脂质体阿霉素在铂耐药卵巢癌患者中的安全性、疗效及预测标志物,并采用模型引导药物开发确定2期推荐剂量。结果显示AVB-500耐受良好,联合紫杉醇的客观缓解率为34.8%,中位缓解持续时间、无进展生存期和总生存期分别为7.0、3.1和10.3个月。亚组分析提示未接受过贝伐珠单抗或AVB-500谷浓度>13.8 mg/L的患者疗效更佳。

要点

  • AVB-500联合紫杉醇或聚乙二醇脂质体阿霉素在铂耐药卵巢癌中耐受良好,未观察到剂量限制性毒性。
  • AVB-500联合紫杉醇的客观缓解率为34.8%,中位无进展生存期3.1个月,中位总生存期10.3个月。
  • 亚组分析显示未接受过贝伐珠单抗或AVB-500谷浓度>13.8 mg/L的患者客观缓解率≥50%,中位无进展生存期≥7.5个月,中位总生存期≥19个月。

核心结论

  • AVB-500联合紫杉醇或聚乙二醇脂质体阿霉素在铂耐药卵巢癌患者中耐受良好,并贡献了紫杉醇的临床活性。
  • 亚组分析识别出可能从AVB-500治疗中获益最大的铂耐药卵巢癌患者人群,将在正在进行的3期试验中进一步评估。

研究设计与样本

  • 1b期研究(NCT03639246),纳入铂耐药卵巢癌患者,接受AVB-500 10、15或20 mg/kg静脉注射每2周一次,联合紫杉醇(n=23)或聚乙二醇脂质体阿霉素(n=30)。
  • 患者治疗至疾病进展或不可耐受毒性,所有患者均随访生存,采用模型引导药物开发方法确定2期推荐剂量。

主要发现

  • 未观察到剂量限制性毒性,三个剂量水平下血清GAS6均被完全抑制。
  • AVB-500联合紫杉醇的客观缓解率为34.8%(8/23,含2例完全缓解),中位缓解持续时间7.0个月,中位无进展生存期3.1个月,中位总生存期10.3个月。
  • 亚组分析显示未接受过贝伐珠单抗或AVB-500谷浓度>13.8 mg/L的患者客观缓解率≥50%,中位无进展生存期≥7.5个月,中位总生存期≥19个月。
  • 采用模型引导药物开发方法确定的AVB-500 2期推荐剂量为15 mg/kg。

关键数值与推荐

  • AVB-500联合紫杉醇的客观缓解率为34.8%(8/23,2例完全缓解),中位缓解持续时间7.0个月,中位无进展生存期3.1个月,中位总生存期10.3个月。
  • 未接受过贝伐珠单抗或AVB-500谷浓度>13.8 mg/L的患者客观缓解率≥50%,中位无进展生存期≥7.5个月,中位总生存期≥19个月。
  • AVB-500的2期推荐剂量为15 mg/kg。

临床怎么用

  • AVB-500联合紫杉醇或聚乙二醇脂质体阿霉素可作为铂耐药卵巢癌的潜在治疗选择,耐受性良好。
  • 临床决策时可关注患者既往贝伐珠单抗使用史及AVB-500谷浓度,以识别可能获益更大的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: GAS6 and AXL are expressed in high-grade serous ovarian cancer but not in normal ovarian tissue. AVB-500, a novel high affinity Fc-sAXL fusion protein, binds GAS6 preventing AXL signaling. This Phase 1b study (NCT03639246) evaluated safety, efficacy, and exploratory predictive markers of AVB-500 combined with paclitaxel (PAC) or pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (PROC), and used a model informed drug development (MIDD) approach for identification of the recommended phase 2 dose (RP2D). METHODS: Eligible patients received AVB-500 at 10, 15, or 20 mg/kg IV q2wk combined with PAC (n = 23) or PLD (n = 30). Patients were treated until progression or unacceptable toxicity. All were followed for survival. RESULTS: No dose limiting toxicities were observed and serum GAS6 was completely suppressed across the three dose levels evaluated. AVB-500 + PAC yielded better clinical activity than AVB-500 + PLD with an ORR of 34.8% (8/23, 2 complete responses) and median DoR, PFS, and OS of 7.0, 3.1, and 10.3 months, respectively. Subgroup analyses showed AVB-500 + PAC patients who had no prior bevacizumab or whose AVB-500 trough levels were >13.8 mg/L exhibited the best clinical response. The ORR and median PFS and OS in patients with these characteristics were ≥50%, ≥7.5 months, and ≥19 months, respectively. Given AVB-500 nor the combination with chemotherapy was expected to cause DLTs, the RP2D of AVB-500 was 15 mg/kg identified using an MIDD approach. CONCLUSION: AVB-500 was well-tolerated in combination with PAC or PLD and contributed to the clinical activity of PAC in PROC patients. Subgroup analyses identified a population of PROC patients who may benefit the most from AVB-500 treatment, which will be further assessed in an ongoing Phase 3 PROC trial.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fuh KC, Bookman MA, Liu JF, et al. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021. PMID: 34474927. doi:10.1016/j.ygyno.2021.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。